Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol-Myers scoops Inhibitex for $2.5bn

This article was originally published in Scrip

Executive Summary

As predicted in the latest Scrip Pharma Trends, the hepatitis C space is hotting up further. Less than two months after Gilead Sciences offered an eye-watering $11 billion to buy Pharmasset, Bristol-Myers Squibb is acquiring Inhibitex for $26 a share, valuing the company at $2.5 billion. The offer represents a 163% premium to the $9.87 Inhibitex share price at the close of markets on 6 January. The Inhibitex board has agreed to not solicit any competing offers for its company.

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts